Santarus, (FRA:TW4A) Total Receivables : €32.6 Mil (As of Sep. 2013)

View and export this data going back to . Start your Free Trial

What is Santarus, Total Receivables?

Santarus,'s Total Receivables for the quarter that ended in Sep. 2013 was €32.6 Mil.

Santarus, Total Receivables Historical Data

The historical data trend for Santarus,'s Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santarus, Total Receivables Chart

Santarus, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Total Receivables

Get a 7-Day Free Trial

9.89

11.15

5.41

15.41

23.64

Santarus, Quarterly Data
	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13
Total Receivables	Get a 7-Day Free Trial															18.11	23.64	35.93	26.56	32.60

Santarus, Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Santarus, Total Receivables Related Terms

Thank you for viewing the detailed overview of Santarus,'s Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Santarus, (FRA:TW4A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.santarus.com

Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Santarus, (FRA:TW4A) Headlines

No Headlines